Close Menu

NEW YORK (GenomeWeb) –  Biocept reported after the close of the market Thursday that its third quarter 2017 revenues rose around 10 percent year over year.

The liquid biopsy assay developer reported total revenues of $1.1 million for the three months ended Sept. 30, up from $1 million in the same period last year.

Of the $1.1 million of revenues recognized during Q3 2017, $900,000 was revenues recognized on an accrual basis and $102,000 reflected the receipt of cash. Biocept converted from cash-based to accrual-based reporting in Q1 of this year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.